- Conditions
- Pain, Postoperative
- Interventions
- XaraColl, Placebo
- Drug · Other
- Lead sponsor
- Innocoll
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 319 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 24
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Anaheim, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 15,652
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia
- Interventions
- filgrastim, busulfan, cyclophosphamide, in vitro-treated bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- Up to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- COVID-19
- Interventions
- Thymalfasin
- Drug
- Lead sponsor
- William B. Ershler, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- CLL
- Interventions
- Zandelisib, Rituximab, Venetoclax
- Drug
- Lead sponsor
- MEI Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Stony Brook, New York • Oklahoma City, Oklahoma + 1 more
- Conditions
- Osteoporosis
- Interventions
- teriparatide, Placebo, BA058 20 µg, BA058 40 µg, BA058 80 µg
- Drug
- Lead sponsor
- Radius Health, Inc.
- Industry
- Eligibility
- 55 Years to 85 Years · Female only
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Myrciaria dubia Prebiotic Supplement, Nivolumab
- Procedure · Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Rotavirus Infection
- Interventions
- Rotarix®, RotaTeq®
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Weeks to 14 Weeks
- Enrollment
- 1,384 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Oakland, California • Atlanta, Georgia • Iowa City, Iowa + 8 more
- Conditions
- Lumbar Spinal Stenosis
- Interventions
- Essential amino acids, Alanine
- Dietary Supplement
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Gastroenteritis
- Interventions
- Omalizumab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years to 76 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Retinal Detachment, Proliferative Vitreoretinopathy
- Interventions
- Bevacizumab
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- Carboplatin, Etoposide, Ibrutinib, Ifosfamide, Laboratory Biomarker Analysis, Pharmacological Study, Rituximab
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Advanced Non-small Cell Lung Cancer, HER2 Mutation
- Interventions
- Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Newport Beach, California • San Diego, California • San Francisco, California + 20 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pemetrexed, Gemcitabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- DCDT2980S, rituximab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 9
- States / cities
- Stanford, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
- Conditions
- Hepatitis B
- Interventions
- IFN-γ 1b (Actimmune), Adefovir dipivoxil, IFN-γ 1b and Adefovir dipivoxil combination
- Drug
- Lead sponsor
- Huntington Medical Research Institutes
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Pasadena, California
- Conditions
- Multiple Myeloma, Plasma Cell Neoplasm
- Interventions
- filgrastim, CD34+ cells, cyclophosphamide, fludarabine phosphate, melphalan, methotrexate, tacrolimus
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Up to 64 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 15
- States / cities
- San Francisco, California • Lewes, Delaware • Newark, Delaware + 12 more
- Conditions
- Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
- Interventions
- ABI-007, Carboplatin
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, R-CHOP regimen, laboratory biomarker analysis, fludeoxyglucose F 18, selective external radiation therapy, yttrium Y 90 ibritumomab tiuxetan
- Biological · Drug · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 240
- States / cities
- Anchorage, Alaska • Tucson, Arizona • Aurora, Colorado + 153 more
- Conditions
- Amyotrophic Lateral Sclerosis, ALS
- Interventions
- probiotic
- Dietary Supplement
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Ibrutinib, Paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Margaret Tempero
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- San Francisco, California • Portland, Oregon
- Conditions
- Uterine Atony, Postpartum Hemorrhage
- Interventions
- Oxytocin
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- Female only
- Enrollment
- 1,798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Prolymphocytic Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Hodgkin Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, T-Cell Chronic Lymphocytic Leukemia, T-Cell Prolymphocytic Leukemia
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cyclosporine, Cytarabine, Etoposide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Mycophenolate Mofetil, Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Therapeutic Autologous Lymphocytes, Total-Body Irradiation
- Procedure · Drug · Other + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2018
- U.S. locations
- 4
- States / cities
- Salt Lake City, Utah • Seattle, Washington
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 45 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- HIV Infection
- Interventions
- Recombinant Interleukin-2
- Drug
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio